Preceding Study Toward Establishing Optimal Blood Concentrations of Mycophenolate Mofetil for Pediatric Steroid-Resistant Nephrotic Syndrome and Pediatric Renal Transplantation
ミコフェノール酸モフェチルの至適血中濃度の確立にむけた先行研究
Preceding Study Toward Establishing Optimal Blood Concentrations of Mycophenolate Mofetil
(2)研究責任医師(多施設共同研究の場合は、研究代表医師)に関する事項等
小野 真里花
Ono Marika
/
自治医科大学
Jichi Medical University Hospital
小児科
329-0498
/
栃木県下野市薬師寺3311-1
3311-1 Yakushiji, Shimotsuke-shi, Tochigi-ken, Japan
0285-44-2111
r1715om@jichi.ac.jp
小野 真里花
Ono Marika
自治医科大学
Jichi Medical University Hospital
小児科
329-0498
栃木県下野市薬師寺3311-1
3311-1 Yakushiji, Shimotsuke-shi, Tochigi-ken, Japan
Children with steroid-resistant nephrotic syndrome or pediatric renal transplant recipients who are currently receiving outpatient care or hospitalized at the Pediatric Department of Jichi Medical University , and who have passed at least 7 days after the introduction of mycophenolate mofetil (MMF).
小児SRNS(寛解導入期、寛解維持期、無効時、再発時、副作用出現時)と小児腎移植治療時(移植導入期、移植導入期拒絶時、移植維持期、移植維持期拒絶時、副作用出現時)のMPAの血中濃度 (MMFを内服する前、内服1時間後、2時間後、3時間後もしくは4時間後、6時間後)から予測される、area under the curve(AUC 0-12 [μg・h/mL])。
The predicted area under the curve (AUC 0-12) of MPA during pediatric SRNS (induction of remission, maintenance of remission, refractory cases, relapse, onset of side effects) and pediatric renal transplant treatment (transplant induction, transplant induction rejection, transplant maintenance, transplant maintenance rejection, onset of side effects) based on MPA blood concentrations (before MMF ingestion, 1 hour after ingestion, 2 hours after ingestion, 3 hours after ingestion or 4 hours after ingestion, 6 hours after ingestion).
The correlation between MPA blood concentration and the following factors: side effects, serum albumin levels, serum creatinine levels, cyclosporine blood concentration, and tacrolimus blood concentration.